FLUENCE CORP. LTD WKN: A2DU34 ISIN: AU000000FLC5 Kürzel: 4SVE Forum: Aktien Thema: Hauptdiskussion

ich habe das Unternehmen jetzt erst kennengelernt, finde die Idee super, werde wohl mal eine kleine Position wagen, nur der Spread von 19,xx% nervt mich.

Bin noch dabei aber aktuell bei -20%

Gibt es hier irgendwelche News oder Aussichten?

Ich habe nichts aktuelles gefunden

ist hier noch jemand investiert?

Q1 2022 Summary The Company is pleased to report significant quarterly sales growth year on year and confirm guidance. Key achievements include: ▪ Q1 Revenues from Continuing Operations of $34.5M1 - Up 116% on Q1 2021. ▪ SPS revenues from Continuing Operations of $7.3M1 - Up 78% on Q1 2021. ▪ Nearly 90% of Q1 SPS revenues from outside China including US, Latin America and Middle East. ▪ CES revenues from Continuing Operations of $25.3M1 - Up 141% on Q1 2021, mainly from the Ivory Coast project. ▪ Cost Efficiency Improvement – Q1 2022 fixed expenses of $6.7M (19% of revenues) versus $6.4M (40% of revenues) in Q1 2021. ▪ Contracted backlog $99.3M of which $75M anticipated to become revenue in 2022. ▪ Cash Balance of $31.1M down from $41.4M at end of 2021 but up from $14.9M at the end of Q1 2021 - Operating cashflow negative $10.4M as expected due to paying vendors with some of the funds already received in Q4 2021. ▪ Guidance – Full year 2022 revenue outlook is $144M, up 40% from $103.2M in 2021. $109.4M or 76% of this anticipated full year revenue is comprised of Q1 revenues plus contracted backlog anticipated to become 2022 revenue. SPS revenues continue to be forecast at $45M, up 22% from $36.9M in 2021. Underlying EBITDA continues to be forecast at $3M, up from $1M in 2021.

Läuft!

Sehr schöne Entwicklung die letzten 3 Monate. Hoffen wir mal dass das nachhaltig ist.

Q4/21 Report https://www.fluencecorp.com/wp-content/uploads/2022/01/ASX-FLC-Q421-update-slides.pdf Q4 Revenues from Continuing Operations of $43.5M - Up 117% on Q3 2021 and 113% on Q4 2020. FY 2021 Revenue from Continuing Operations of $103.2M - Grew by 18% over FY2020. Guidance Met for Revenue and Positive Underlying EBITDA2 – SPS revenues for FY 2021 from continuing and discontinued operations were $39.6M versus guidance of $35-50M. Underlying EBITDA positive $1.0M in FY2021. SPS backlog entering 2022 is 65% higher than that entering 2021. § MABR Sold Capacity Increased 56% - 313 plants sold to date (up from 245) with total treatment capacity to treat wastewater for almost 1 million people (up from 600,000).

Gibt es hier Hoffnung das es mal nach oben geht??